Laboratorios Farmaceuticos ROVI Total Assets
Laboratorios Farmaceuticos ROVI total assets. Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) holds total assets worth €922.07 Million EUR (≈ $1.08 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Laboratorios Farmaceuticos ROVI market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Laboratorios Farmaceuticos ROVI (2003–2024)
Total assets of Laboratorios Farmaceuticos ROVI from 2003 to 2024. This chart illustrates how Laboratorios Farmaceuticos ROVI's total assets have evolved over time, based on quarterly financial data. See ROVI live share price for real-time trading data and today's change.
Laboratorios Farmaceuticos ROVI - Asset Composition Analysis
Laboratorios Farmaceuticos ROVI Total Assets Breakdown (December 2024)
Laboratorios Farmaceuticos ROVI total assets breakdown as of December 2024. Laboratorios Farmaceuticos ROVI's total assets of €922.07 Million consist of 59.1% current assets and 40.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 3.3% |
| Accounts Receivable | €129.50 Million | 15.6% |
| Inventory | €329.95 Million | 39.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €33.95 Million | 4.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Laboratorios Farmaceuticos ROVI's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ROVI working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Laboratorios Farmaceuticos ROVI's current assets represent 59.1% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2024, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 39.7% of total assets.
Laboratorios Farmaceuticos ROVI Competitors by Total Assets
Key competitors of Laboratorios Farmaceuticos ROVI based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Laboratorios Farmaceuticos ROVI - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 2.50 | 2.97 |
| Quick Ratio | 1.32 | 0.94 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €373.77 Million | €332.34 Million | €241.69 Million |
Laboratorios Farmaceuticos ROVI - Advanced Valuation Insights
This section examines the relationship between Laboratorios Farmaceuticos ROVI's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.99 |
| Latest Market Cap to Assets Ratio | 4.50 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | €832.02 Million |
| Market Capitalization | $3.74 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Laboratorios Farmaceuticos ROVI's assets at a significant premium (4.50x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Laboratorios Farmaceuticos ROVI's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Laboratorios Farmaceuticos ROVI (2003–2024)
The table below shows the annual total assets of Laboratorios Farmaceuticos ROVI from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €832.02 Million ≈ $972.72 Million |
+4.02% |
| 2023-12-31 | €799.88 Million ≈ $935.15 Million |
-8.97% |
| 2022-12-31 | €878.70 Million ≈ $1.03 Billion |
+19.93% |
| 2021-12-31 | €732.68 Million ≈ $856.58 Million |
+27.55% |
| 2020-12-31 | €574.44 Million ≈ $671.58 Million |
+12.37% |
| 2019-12-31 | €511.21 Million ≈ $597.66 Million |
+26.95% |
| 2018-12-31 | €402.70 Million ≈ $470.80 Million |
+34.96% |
| 2017-12-31 | €298.38 Million ≈ $348.84 Million |
+3.66% |
| 2016-12-31 | €287.85 Million ≈ $336.52 Million |
+9.10% |
| 2015-12-31 | €263.85 Million ≈ $308.46 Million |
+0.97% |
| 2014-12-31 | €261.32 Million ≈ $305.51 Million |
+10.76% |
| 2013-12-31 | €235.92 Million ≈ $275.82 Million |
+6.10% |
| 2012-12-31 | €222.36 Million ≈ $259.97 Million |
-2.50% |
| 2011-12-31 | €228.07 Million ≈ $266.64 Million |
+7.13% |
| 2010-12-31 | €212.89 Million ≈ $248.89 Million |
+28.31% |
| 2009-12-31 | €165.91 Million ≈ $193.97 Million |
+37.63% |
| 2008-12-31 | €120.55 Million ≈ $140.93 Million |
+7.48% |
| 2007-12-31 | €112.16 Million ≈ $131.13 Million |
+47.50% |
| 2006-12-31 | €76.04 Million ≈ $88.90 Million |
-100.00% |
| 2005-12-31 | €8.15 Trillion ≈ $9.53 Trillion |
+103335.75% |
| 2004-12-31 | €7.88 Billion ≈ $9.21 Billion |
+16113.55% |
| 2003-12-31 | €48.60 Million ≈ $56.82 Million |
-- |
About Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more